Dyax Corp. (DYAX) Appoints Marc Kozin to Board of Directors
10/16/2012 10:00:40 AM
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today the appointment of Marc Kozin to its Board of Directors. “Marc brings to our Board nearly 30 years of domestic and international experience in strategy consulting and a deep understanding of our industry,” said Henry E. Blair, Chairman of Dyax’s Board of Directors. “His expertise and record of success in advising life sciences companies will provide the Board with a new and valued perspective as we continue to grow our KALBITOR® (ecallantide) business, expand our angioedema portfolio and leverage our Licensing and Funded Research Program.” For 15 years, Mr. Kozin was North American President of L.E.K. Consulting, a global management consulting firm that uses deep industry expertise and analytical rigor to help clients solve their most critical business problems. Mr. Kozin led the development of L.E.K.’s biopharmaceutical & life sciences practice, where he advised biopharmaceutical leaders on strategic issues facing their organizations, including, acquisition opportunities and target screening, licensing and joint ventures, portfolio optimization, product planning and commercialization, and domestic and global marketing strategies. Mr. Kozin also serves on the boards of Endocyte, Medical Simulation Corporation, UFP Technologies, CrunchTime! Information Systems, Inc. and DukeEngage.